Acip.Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. MMWR. 1991;40 (RR-1):1-7.
2.
American Academy of Pediatrics.Active and passive immunization. In: Peter G, ed. 1994 Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 1994:1-67.
3.
Acip.Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR.1991; 40(RR-13):1-25.
4.
AAP News. 1989; July:6-7.
5.
Acip.Measles prevention: recommendations of the Advisory Committee on Immunization Practices (ACIP) . MMWR.1989;38(S-9):1-13.
6.
Acip.Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use — supplementary ACIP statement. ACIP. 1992;41 (RR-1):1-10.
7.
Hardy GE, Hopkins CC, Linnemann CC, et al. Trivalent oral poliovirus vaccine: a comparison of two infant immunization schedules. Pediatrics. 1970;45: 444-448.
8.
Cohen-Abbo A. , Culley BS, Reed GW, et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediat Infect Dis J. 1995. In press.
9.
Faden H., Modlin JF, Thomas ML, et al. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis.1990;162:1291-1297.
10.
McBean AM, Thoms ML, Albrecht P., et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol.1988; 128:615-628.
11.
Modlin JF, Halsey NA, Thoms ML, et al. Serum neutralizing antibody response to three experimental sequential IPV-OPV immunization schedules. Presented at the 33rd International Conference on Antimicrobial Agents and Chemotherapy. Abstract #1239. New Orleans, LA. October 1993 .
12.
Lennon JL, Black FLMaternally derived measles immunity in era of vaccine-protected mothers . J Pediatr.1986;108:671-676.
13.
Jenks PJ, Caul EO, Roome APCH. Maternally derived measles immunity in children of naturally infected and vaccinated mothers. Epidem Infect. 1988 ;101:473-476.
14.
King GE, Markowitz LEA comparison ofseroconversion rates to MMRvaccine of children vaccinated at 9, 12, or 15 months of age. Presented at the 34th International Conference on Antimicrobial Agents and Chemotherapy. Abstract #H108. Orlando, FL. September, 1994 .
15.
Centers for Disease Control and Prevention.General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1994;43 (No. RR-1):1-38.
16.
Committee on Infectious Diseases, American Academy of Pediatrics.Universal hepatitis B immunization . Pediatrics.1992;89:795-800.
17.
Keyserling HL, West DJ, Hesley TM, et al. Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve or fifteen months of age. J Pediatr.1994;125:67-69.
18.
Jilg W., Schmidt M., Deinhardt F.Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis.1989;160:766-769.
19.
Stevens CD, Toy PT, Taylor PE, et al. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics . 1992;20(Suppl):170-173.
20.
Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population . JAMA.1989;261:2362-2366.
21.
Jilg W., Schmidt M., Deinhardt F.Persistence of specific antibodies after hepatitis B vaccination. J HepatoL1988;6:201-207.
22.
Gergen PJ, McQuillan GM, Kiely M., et al. A population-based serological survey of tetanus immunity: implications for U.S. vaccination policy. N Engl J Med. Submitted for publication.
23.
Steinhoff MC , Thomas ML, Dannelfelser S., O'Donovan C.Immunogenicity of H. influenzae type B-CRM197 conjugate vaccine (HbOC) given simultaneously with routine childhood immunizations . Pediatr Res.1990;27:184A.
24.
Dashefsky B. , Wald E., Guerra N., Byers C.Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. Pediatrics.1990;85 (Suppl):682-689.
25.
Deforest A. , Long SS, Lischner HW, et al. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics. 1988;81:237-246.
26.
Berger R., Just M.Lack of interference between vaccines. Pediatr Infect Dis J.1983;2:172. Letter.
27.
Booy R., Moxon ER, MacFarlane JA et al. Efficacy of Haemophilus influenza type B conjugate vaccine in Oxford re. gion. Lancet.1992;340:847. Letter.
28.
Greenberg DP , Vadheim SM, Marcy SM, et al. Safety and immunogenicity of two recombinant hepatitis B vaccines given to 5000 infants as part of routine immunization at 2, 4, and 6 months of age. In: Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents andChemotherapy. Chicago, IL: September 29 to October 2, 1991.
29.
Huang LM, Lee CY, Hsu CY, et al. Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine . Pediatry Infect Dis J.1990;9:461-465.
30.
Barone P., Mauro L., Leonardi S., et al. Simultaneous administration of HB recombinant vaccine with diphtheria and tetanus toxoid and oral polio vaccine: a pilot study. Acta Paediatr Jpn.1991;33:455-458.
31.
Greenberg DP , Vadheim CM, Marcv SM, et al. Comparative safety and immunogenicity of two recombinant hepatitis B (HBV) vaccines given to infants at 2, 4, and 6 months of age (Abstract no. 920). 1992; ICAAC:264.
32.
King GE, Hadler SCSimultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J.1994;13:394-407.
